 Thomas Jensen
Concepts (137)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Glucagon-Like Peptides | 6 | 2024 | 58 | 1.060 |
Why?
| | Glucagon-Like Peptide 1 | 1 | 2025 | 135 | 0.850 |
Why?
| | Fatty Liver | 1 | 2025 | 243 | 0.780 |
Why?
| | Stroke Volume | 5 | 2024 | 617 | 0.610 |
Why?
| | Atrial Fibrillation | 3 | 2024 | 390 | 0.470 |
Why?
| | Obesity | 8 | 2024 | 2993 | 0.460 |
Why?
| | Liraglutide | 3 | 2020 | 30 | 0.440 |
Why?
| | Atrial Premature Complexes | 2 | 2004 | 3 | 0.430 |
Why?
| | Heart Failure | 5 | 2024 | 2237 | 0.430 |
Why?
| | Diabetes Mellitus, Type 2 | 6 | 2024 | 2534 | 0.330 |
Why?
| | Metabolic Syndrome | 2 | 2025 | 354 | 0.310 |
Why?
| | Natriuretic Peptide, Brain | 2 | 2024 | 99 | 0.260 |
Why?
| | Double-Blind Method | 9 | 2024 | 1997 | 0.250 |
Why?
| | Incretins | 1 | 2025 | 22 | 0.230 |
Why?
| | Bridged Bicyclo Compounds, Heterocyclic | 3 | 2013 | 227 | 0.220 |
Why?
| | Tachycardia, Paroxysmal | 1 | 2003 | 7 | 0.210 |
Why?
| | Diabetic Angiopathies | 3 | 2020 | 259 | 0.200 |
Why?
| | Liver Cirrhosis | 1 | 2025 | 316 | 0.200 |
Why?
| | Body Composition | 3 | 2013 | 684 | 0.190 |
Why?
| | Non-alcoholic Fatty Liver Disease | 1 | 2025 | 279 | 0.180 |
Why?
| | Cardiovascular Diseases | 3 | 2023 | 2111 | 0.180 |
Why?
| | Receptors, Vasopressin | 1 | 2021 | 20 | 0.170 |
Why?
| | Vasopressins | 1 | 2021 | 64 | 0.170 |
Why?
| | Quality of Life | 3 | 2023 | 2894 | 0.170 |
Why?
| | Fructose | 1 | 2021 | 112 | 0.170 |
Why?
| | Peptide Fragments | 1 | 2024 | 706 | 0.160 |
Why?
| | Cardiovascular System | 1 | 2020 | 137 | 0.150 |
Why?
| | Hypoglycemic Agents | 4 | 2023 | 1294 | 0.140 |
Why?
| | Weight Loss | 3 | 2013 | 788 | 0.130 |
Why?
| | Metformin | 1 | 2020 | 331 | 0.130 |
Why?
| | Aldehyde Reductase | 1 | 1996 | 29 | 0.130 |
Why?
| | Aged | 12 | 2024 | 24001 | 0.110 |
Why?
| | Angiotensin-Converting Enzyme Inhibitors | 1 | 1996 | 201 | 0.110 |
Why?
| | Naltrexone | 1 | 2015 | 97 | 0.110 |
Why?
| | Electrocardiography, Ambulatory | 2 | 2004 | 63 | 0.100 |
Why?
| | Humans | 25 | 2025 | 137782 | 0.100 |
Why?
| | Treatment Outcome | 7 | 2024 | 10837 | 0.100 |
Why?
| | Narcotic Antagonists | 1 | 2015 | 181 | 0.100 |
Why?
| | Middle Aged | 12 | 2024 | 33554 | 0.090 |
Why?
| | Anti-Obesity Agents | 2 | 2009 | 57 | 0.090 |
Why?
| | Diabetes Mellitus, Type 1 | 3 | 2016 | 3717 | 0.090 |
Why?
| | Male | 16 | 2024 | 67906 | 0.090 |
Why?
| | Factor VIII | 1 | 2010 | 98 | 0.080 |
Why?
| | Female | 14 | 2024 | 73465 | 0.070 |
Why?
| | Alcoholism | 1 | 2015 | 809 | 0.070 |
Why?
| | Hyperlipidemias | 2 | 2000 | 120 | 0.060 |
Why?
| | Bundle-Branch Block | 1 | 2005 | 31 | 0.060 |
Why?
| | Drug Therapy, Combination | 2 | 2020 | 1067 | 0.060 |
Why?
| | Anticoagulants | 1 | 2010 | 664 | 0.060 |
Why?
| | Ventricular Fibrillation | 1 | 2005 | 60 | 0.060 |
Why?
| | Systole | 1 | 2005 | 189 | 0.060 |
Why?
| | Prevalence | 2 | 2020 | 2734 | 0.060 |
Why?
| | Sodium Potassium Chloride Symporter Inhibitors | 1 | 2024 | 16 | 0.060 |
Why?
| | Diuretics | 1 | 2024 | 74 | 0.050 |
Why?
| | Adult | 10 | 2020 | 38023 | 0.050 |
Why?
| | Tachycardia, Ventricular | 1 | 2005 | 175 | 0.050 |
Why?
| | Catheter Ablation | 2 | 2005 | 350 | 0.050 |
Why?
| | Neoplasms | 1 | 2018 | 2673 | 0.050 |
Why?
| | Antibodies, Monoclonal | 1 | 2010 | 1430 | 0.050 |
Why?
| | Statistics, Nonparametric | 1 | 2003 | 431 | 0.050 |
Why?
| | Cytochrome c Group | 1 | 2002 | 43 | 0.050 |
Why?
| | Pseudomonas | 1 | 2002 | 31 | 0.050 |
Why?
| | Randomized Controlled Trials as Topic | 2 | 2020 | 1478 | 0.050 |
Why?
| | Fructokinases | 1 | 2021 | 32 | 0.040 |
Why?
| | Hep G2 Cells | 1 | 2021 | 67 | 0.040 |
Why?
| | Drinking | 1 | 2021 | 42 | 0.040 |
Why?
| | Arteriosclerosis | 2 | 1997 | 88 | 0.040 |
Why?
| | Placebos | 1 | 2018 | 199 | 0.040 |
Why?
| | Injections, Subcutaneous | 1 | 2016 | 157 | 0.030 |
Why?
| | Albuminuria | 1 | 1997 | 185 | 0.030 |
Why?
| | Denmark | 3 | 2008 | 46 | 0.030 |
Why?
| | Case-Control Studies | 1 | 2003 | 3569 | 0.030 |
Why?
| | Diabetic Neuropathies | 1 | 1996 | 94 | 0.030 |
Why?
| | Aged, 80 and over | 2 | 2018 | 7637 | 0.030 |
Why?
| | Prospective Studies | 2 | 2005 | 7623 | 0.030 |
Why?
| | Clinical Trials, Phase III as Topic | 1 | 2015 | 106 | 0.030 |
Why?
| | Young Adult | 4 | 2016 | 13240 | 0.030 |
Why?
| | Prognosis | 2 | 2020 | 4039 | 0.030 |
Why?
| | Mice, Knockout | 1 | 2021 | 3018 | 0.030 |
Why?
| | Hyperlipidemia, Familial Combined | 1 | 1993 | 3 | 0.030 |
Why?
| | Adolescent | 5 | 2016 | 21574 | 0.030 |
Why?
| | Inflammation | 1 | 2023 | 2838 | 0.020 |
Why?
| | Liver | 1 | 2021 | 1943 | 0.020 |
Why?
| | Follow-Up Studies | 2 | 2018 | 5136 | 0.020 |
Why?
| | Chemistry, Clinical | 1 | 1990 | 12 | 0.020 |
Why?
| | Hospitalization | 1 | 2020 | 2200 | 0.020 |
Why?
| | Disease Models, Animal | 1 | 2021 | 4295 | 0.020 |
Why?
| | Metabolic Clearance Rate | 1 | 2010 | 115 | 0.020 |
Why?
| | Sweat Glands | 1 | 1990 | 4 | 0.020 |
Why?
| | Half-Life | 1 | 2010 | 164 | 0.020 |
Why?
| | Cell Transformation, Viral | 1 | 1990 | 25 | 0.020 |
Why?
| | Mice, Inbred C57BL | 1 | 2021 | 5764 | 0.020 |
Why?
| | Area Under Curve | 1 | 2010 | 314 | 0.020 |
Why?
| | Risk Factors | 3 | 2018 | 10407 | 0.020 |
Why?
| | Nasal Polyps | 1 | 1990 | 59 | 0.020 |
Why?
| | Lipoproteins | 1 | 1990 | 168 | 0.020 |
Why?
| | Alcohol Drinking | 1 | 2015 | 828 | 0.020 |
Why?
| | Caloric Restriction | 1 | 2008 | 124 | 0.020 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2010 | 2057 | 0.020 |
Why?
| | Insulin | 1 | 2016 | 2411 | 0.010 |
Why?
| | Hemorrhage | 1 | 2010 | 722 | 0.010 |
Why?
| | Lipids | 1 | 1990 | 673 | 0.010 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2010 | 804 | 0.010 |
Why?
| | Syndrome | 1 | 2005 | 358 | 0.010 |
Why?
| | Mice | 1 | 2021 | 17794 | 0.010 |
Why?
| | Logistic Models | 1 | 2008 | 2075 | 0.010 |
Why?
| | Radiography | 1 | 2005 | 822 | 0.010 |
Why?
| | Retrospective Studies | 1 | 2020 | 15682 | 0.010 |
Why?
| | Guanidine | 1 | 2002 | 21 | 0.010 |
Why?
| | Calorimetry, Differential Scanning | 1 | 2002 | 37 | 0.010 |
Why?
| | Electrocardiography | 1 | 2005 | 629 | 0.010 |
Why?
| | Protein Denaturation | 1 | 2002 | 74 | 0.010 |
Why?
| | Spectrophotometry | 1 | 2002 | 61 | 0.010 |
Why?
| | Circular Dichroism | 1 | 2002 | 149 | 0.010 |
Why?
| | Controlled Clinical Trials as Topic | 1 | 2000 | 30 | 0.010 |
Why?
| | Protein Folding | 1 | 2002 | 280 | 0.010 |
Why?
| | Hypolipidemic Agents | 1 | 2000 | 91 | 0.010 |
Why?
| | Cystic Fibrosis | 1 | 1990 | 1114 | 0.010 |
Why?
| | Protein Structure, Tertiary | 1 | 2002 | 861 | 0.010 |
Why?
| | Time Factors | 1 | 2009 | 6834 | 0.010 |
Why?
| | Animals | 1 | 2021 | 36951 | 0.010 |
Why?
| | Kinetics | 1 | 2002 | 1670 | 0.010 |
Why?
| | Models, Molecular | 1 | 2002 | 1570 | 0.010 |
Why?
| | Practice Guidelines as Topic | 1 | 2000 | 1586 | 0.010 |
Why?
| | Cell Line, Transformed | 1 | 1990 | 145 | 0.000 |
Why?
| | Keratins | 1 | 1990 | 173 | 0.000 |
Why?
| | Microscopy, Electron | 1 | 1990 | 443 | 0.000 |
Why?
| | Reference Values | 1 | 1990 | 816 | 0.000 |
Why?
| | Cell Division | 1 | 1990 | 794 | 0.000 |
Why?
| | Cohort Studies | 1 | 1997 | 5750 | 0.000 |
Why?
| | Cell Survival | 1 | 1990 | 1120 | 0.000 |
Why?
| | Epithelial Cells | 1 | 1990 | 1096 | 0.000 |
Why?
| | DNA | 1 | 1990 | 1459 | 0.000 |
Why?
| | Infant, Newborn | 1 | 1993 | 6084 | 0.000 |
Why?
| | Infant | 1 | 1993 | 9482 | 0.000 |
Why?
| | Child, Preschool | 1 | 1993 | 11105 | 0.000 |
Why?
| | Child | 1 | 1993 | 21989 | 0.000 |
Why?
|
|
Jensen's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|